Full-Time

VP – Regulatory Affairs

Oncology & INT

Posted on 5/8/2025

Moderna

Moderna

5,001-10,000 employees

Develops mRNA-based medicines for health

No salary listed

Senior, Expert

Cambridge, MA, USA

70% in-office structure required for collaboration and mentorship.

Category
Risk & Compliance
Legal & Compliance
Connection
Connection
Connection
logo

Get referrals →

You have ways to get a Moderna referral from your network.

💡

Applications through a referral are 3x more likely to get an interview!

Requirements
  • BA/BS degree in a scientific/engineering discipline required; Masters or PhD preferred.
  • Minimum of 15 years of regulatory experience in biotech, pharma, or clinical research organizations, with 12+ years in regulatory strategy.
  • In-depth knowledge of relevant FDA, EU, ICH guidelines, and regulations, particularly for oncology and individualized therapies.
  • Proven experience with regulatory filings and negotiations with FDA and international health authorities.
  • Excellent communication skills and the ability to convey complex regulatory issues clearly.
  • Strong leadership and team management skills.
  • Ability to work independently and manage multiple projects in a fast-paced environment.
Responsibilities
  • Design and execute the strategic vision for regulatory affairs in Oncology and INT, ensuring alignment with Moderna’s global business objectives.
  • Oversee the preparation, submission, and approval processes for regulatory filings, including IND amendments and supplements.
  • Monitor regulatory developments and provide guidance to project teams regarding the implementation of regulatory strategies.
  • Establish and maintain relationships with regulatory agencies, respond to requests for additional data, and negotiate with regulatory authorities.
  • Develop and implement regulatory policies and practices in compliance with federal and international guidelines.
  • Manage and develop a high-performing regulatory team, ensuring the team is equipped to meet regulatory milestones.
  • Partner with internal teams and external partners to manage submissions and ensure regulatory compliance.
  • Serve as the global regulatory lead, accountable for all regulatory aspects of assigned projects, including the development and implementation of global regulatory development plans.
  • Effectively communicate regulatory strategies, risks, and plans to the GRS, project development teams, and senior management.
  • Ensure appropriate levels of resources and manage the regulatory budget.
  • Identify and implement process improvements to enhance regulatory practices.
Desired Qualifications
  • A desire to be part of a high-growth, transformational company that is Bold, Relentless, Curious, and Collaborative.

Moderna focuses on developing medicines using messenger RNA (mRNA), which is a crucial component in how cells produce proteins necessary for various biological functions. Their products work by delivering mRNA into the body, which instructs cells to create specific proteins that can help prevent or treat diseases. This approach is different from traditional medicines, as it leverages the body's own processes to generate therapeutic proteins. Moderna aims to create a new category of medicines that can significantly enhance patient care and improve health outcomes.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2010

Simplify Jobs

Simplify's Take

What believers are saying

  • Moderna's RSV vaccine approval in Australia and UK expands its respiratory disease portfolio.
  • The 2027 launch of a cancer vaccine with Merck positions Moderna in oncology.
  • Biomanufacturing training programs enhance workforce capabilities for mRNA production.

What critics are saying

  • Allegations of bribing children for trials could damage Moderna's reputation.
  • Patent lawsuit with Pfizer and BioNTech may lead to financial liabilities.
  • Halt of Project NextGen work raises concerns about COVID-19 initiative funding.

What makes Moderna unique

  • Moderna is pioneering mRNA as a new class of medicines.
  • The company has expanded its pipeline beyond COVID-19 to include cancer and RSV.
  • Moderna collaborates with Benchling to enhance AI-driven mRNA research.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

Sabbatical Leave

Hybrid Work Options

401(k) Company Match

Parental Leave

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Wellness Program

Mental Health Support

Phone/Internet Stipend

Home Office Stipend

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

5%
Things of Business
May 7th, 2025
Benchling and Moderna Collaborate on AI-Driven Research

SAN FRANCISCO and BOSTON, May 7, 2025 - Benchling, the R&D platform powering the biotech industry, today announced an expanded collaboration with Moderna.

Labiotech
May 2nd, 2025
From Pandemic Spotlight To Post-Covid Crossroads: What Happened To These Biotech Players?

Newsletter Signup - Under Article / In Page"*" indicates required fields In the heat of the COVID-19 crisis, a wave of vaccine companies stepped into the spotlight with unprecedented speed and visibility. Riding a surge of public and private funding, they raced to develop vaccines and therapeutics that could curb a once-in-a-century global emergency. While pharma giants like AstraZeneca and Johnson Johnson also played prominent roles, much of the momentum and risk was carried by smaller biotech players suddenly thrown onto the global stage. For a brief moment, it seemed like these companies might reshape the pharmaceutical landscape for good.Fast forward to 2025, and the picture is far more complex.Some, like Moderna and BioNTech, used the momentum to build expansive pipelines beyond COVID-19, branching into cancer, flu, RSV, and other diseases. Others, however, are now scaling down, pivoting, or fading from view entirely. Just this month, companies including GeoVax, CastleVax, and Vaxart revealed they were told to halt their government-backed work on next-generation COVID vaccines under the Biden-era Project NextGen, casting doubt on the long-term strategic value of these initiatives

Pulmonology Advisor
Apr 30th, 2025
HHS Announces Plans to Pay Moderna $176 Million for mRNA Flu Vaccine

Moderna is testing a pandemic-focused vaccine for avian influenza A(H5N1).

Slay News
Apr 27th, 2025
Moderna Faces Ban for Bribing Children to Join Covid 'Vaccine' Trials

Moderna could face suspension over the practices deemed "unacceptable" by regulators.

Notas de Prensa
Apr 7th, 2025
Moderna to showcase its extensive research on Infectious Diseases at ESCMID 2025.

Moderna, Inc. (NASDAQ:MRNA) announces that it will present at the World Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), which will be held in Vienna, Austria, from April 11 to 15, 2025, its research in multiple areas of infectious diseases, such as COVID-19, influenza, respiratory syncytial virus, cytomegalovirus, norovirus, and mpox.